Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey in Unresectable BRAF-mutant Melanoma
jRCT2011210010Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of encorafenib and binimetinib in melanoma, sponsored by Ono Pharmaceutical. Primary endpoints: Occurrence of adverse drug reactions and infections, Occurrence of adverse drug reactions corresponding to specified safety concerns and 1 more. Started Feb 2019; status: completed.
02
Drugs
encorafenibbinimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2011210010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210010.